Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MALARONE PEDIATRIC vs ARAKODA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MALARONE PEDIATRIC is a fixed-dose combination of atovaquone and proguanil. Atovaquone selectively inhibits the mitochondrial electron transport chain of Plasmodium species at the cytochrome bc1 complex, collapsing mitochondrial membrane potential and disrupting pyrimidine synthesis. Proguanil is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase in the parasite, blocking DNA synthesis. The combination synergistically kills blood-stage schizonts and inhibits liver-stage hypnozoites of P. falciparum.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
Treatment of acute, uncomplicated Plasmodium falciparum malaria,Prophylaxis of Plasmodium falciparum malaria
Radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection
Adults: 250 mg atovaquone/100 mg proguanil orally once daily for 3 consecutive days for treatment; for prophylaxis, 250 mg/100 mg orally once daily starting 1-2 days before travel and continued for 7 days after leaving endemic area.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Atovaquone: terminal half-life 1.5-3 days (range 2-3 days in adults, longer in children). Proguanil: terminal half-life 12-21 hours (parent drug) and 14-23 hours (cycloguanil). Clinically, atovaquone's long half-life supports single daily dosing.
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Atovaquone undergoes minimal metabolism, with glucuronidation as a minor pathway, and is primarily excreted unchanged in feces. Proguanil is hepatically metabolized via CYP2C19 to its active metabolite cycloguanil, and to a lesser extent by CYP3A4.
Primarily metabolized by CYP2D6 and monoamine oxidase (MAO). Tafenoquine undergoes extensive metabolism including N-dealkylation and oxidation.
Atovaquone: >90% excreted unchanged in feces via biliary elimination; <1% renal. Proguanil: ~40-60% excreted renally as unchanged drug and active metabolite cycloguanil; ~30% fecal.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Atovaquone: >99% bound to plasma proteins. Proguanil: ~75% bound to plasma proteins.
~99.5% bound to human serum albumin (HSA); binding is high and saturable, with unbound fraction slightly increasing at high concentrations.
Atovaquone: Vd ~0.6-1.0 L/kg (extensive tissue distribution). Proguanil: Vd ~0.2-0.5 L/kg.
Apparent Vd: ~2000 L (or ~24-30 L/kg based on 70 kg), indicating extensive tissue distribution (concentrated in red blood cells, liver, lungs, and adipose tissue).
Atovaquone: Oral bioavailability highly variable (range 10-50%) but improved with fatty food; ~23% in fasted state, increased ~2-fold with high-fat meal. Proguanil: Oral bioavailability ~70-90%.
Oral: ~100% (absolute bioavailability not formally determined, but absorption is complete with minimal first-pass metabolism; relative bioavailability is high based on AUC and clinical efficacy).
For prophylaxis: If Cr Cl 30-50 m L/min, reduce dose to half the standard adult dose; if Cr Cl <30 m L/min, use alternative agent. For treatment: If Cr Cl 30-50 m L/min, reduce dose to half the standard adult dose; if Cr Cl <30 m L/min, use alternative agent.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not recommended for severe renal impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). For severe hepatic impairment (Child-Pugh C), use with caution due to limited data; no specific dose recommendation available.
Contraindicated in Child-Pugh Class B or C. Use with caution in mild hepatic impairment (Child-Pugh Class A) with no dose adjustment.
Children ≥5 kg: For treatment, 20 mg/kg atovaquone/8 mg/kg proguanil orally once daily for 3 days. For prophylaxis, 20 mg/kg atovaquone/8 mg/kg proguanil orally once daily. Dosing based on weight: 5-8 kg: pediatric tablet (62.5 mg/25 mg) daily; 9-10 kg: 1.5 pediatric tablets daily; 11-20 kg: 2 pediatric tablets daily; 21-30 kg: 3 pediatric tablets daily; 31-40 kg: 4 pediatric tablets daily; >40 kg: adult tablet (250 mg/100 mg) daily.
Safety and efficacy not established in pediatric patients (<18 years).
No specific dose adjustment required based on age alone; use standard adult dosing, but consider renal function as older adults may have reduced creatinine clearance. Monitor for adverse effects, particularly gastrointestinal.
No specific dose adjustment; use with monitoring for renal function due to age-related decline and potential for increased adverse effects.
None
ARAKODA can cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. G6PD testing must be performed before prescribing due to risk of hemolytic anemia.
Not recommended for severe malaria or cerebral malaria,May cause hypersensitivity reactions, including angioedema and anaphylaxis,Avoid in patients with severe renal impairment (Cr Cl <30 m L/min) due to risk of accumulation of proguanil,May cause hepatotoxicity; monitor liver function in prolonged use,May cause gastrointestinal disturbances; administer with food,Parasite resistance may develop; monitor for clinical failure
Hemolytic anemia in G6PD-deficient patients (contraindicated in G6PD deficiency without prior testing),Methemoglobinemia (rare, monitor for cyanosis and dyspnea),Psychiatric effects including anxiety, depression, and insomnia,Hepatotoxicity (rare, monitor liver function),Use in pregnancy: not recommended (risk of hemolysis in G6PD-deficient fetus),Lactation: avoid if breastfeeding infant is G6PD deficient
Hypersensitivity to atovaquone, proguanil, or any component,Severe renal impairment (Cr Cl <30 m L/min) for prophylaxis,Concurrent use with rifampin or rifabutin (may reduce atovaquone levels)
G6PD deficiency (without confirmed normal G6PD activity),Known hypersensitivity to tafenoquine or any 8-aminoquinoline,Use in children <16 years (safety not established),Severe renal impairment (e GFR <30 m L/min),Lactation in infants with G6PD deficiency or unknown G6PD status
Take with food or milk to increase atovaquone absorption. Avoid high-fat meals immediately before or after dosing as they may slightly delay absorption but overall increase bioavailability. No known significant food-drug interactions with proguanil.
Take with a fatty meal to increase absorption. No specific dietary restrictions. Avoid grapefruit juice as it may alter metabolism.
MALARONE PEDIATRIC contains atovaquone and proguanil. Atovaquone is not teratogenic in animals, but proguanil is associated with increased risk of neural tube defects and other congenital anomalies if used in the first trimester. Data in humans are limited; it should only be used if benefit outweighs risk. Pregnancy category C.
FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.
Atovaquone and proguanil are excreted in breast milk in low concentrations, but no adverse effects have been reported. M/P ratio not established. Consider risk-benefit; caution in infants with G6PD deficiency. Discontinue breastfeeding or drug if infant develops hemolysis.
Excreted in human milk; M/P ratio unknown. Potential for adverse effects in infant; use caution, consider discontinuing breastfeeding.
No specific dosing adjustments are recommended for pregnancy. However, pharmacokinetic changes in pregnancy (e.g., increased clearance) may require monitoring for therapeutic efficacy.
No established dose adjustments; pharmacokinetic changes in pregnancy may require monitoring drug levels and clinical response.
Malarone Pediatric (atovaquone/proguanil) is indicated for prophylaxis and treatment of acute, uncomplicated P. falciparum malaria. Prophylaxis should start 1-2 days before travel, continued during stay, and for 7 days after leaving endemic area. Administer with food or milk to enhance absorption. Not recommended for children <5 kg. Avoid use for malaria treatment in patients with severe renal impairment (Cr Cl <30 m L/min). Monitor for signs of hepatotoxicity, especially in patients with pre-existing liver disease.
ARAKODA (tafenoquine) is indicated for radical cure of Plasmodium vivax malaria. Assess G6PD status before prescribing; contraindicated in G6PD-deficient patients due to hemolytic anemia risk. Monitor for methemoglobinemia. Avoid use in pregnancy/lactation. Take with food to enhance absorption.
Take this medication exactly as prescribed, with food or milk to improve absorption and reduce stomach upset.,For prevention: start 1-2 days before entering malarious area, continue while there, and for 7 days after leaving.,Complete full course even if feeling better; do not skip doses.,Use additional protective measures like insect repellent and bed nets.,Contact doctor immediately if signs of malaria (fever, chills, headache) occur during or after travel.,Report any rash, mouth ulcers, easy bruising/bleeding, or yellowing of eyes/skin.,Keep out of reach of children; overdose can be fatal.
Take with food to improve absorption.,You must be tested for G6PD deficiency before starting this medication.,Report any signs of anemia, dark urine, or yellowing of eyes/skin.,Avoid use during pregnancy or breastfeeding.,Do not drive if you experience dizziness or blurred vision.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MALARONE PEDIATRIC vs ARAKODA, answered by our medical review team.
MALARONE PEDIATRIC is a Antimalarial that works by MALARONE PEDIATRIC is a fixed-dose combination of atovaquone and proguanil. Atovaquone selectively inhibits the mitochondrial electron transport chain of Plasmodium species at the cytochrome bc1 complex, collapsing mitochondrial membrane potential and disrupting pyrimidine synthesis. Proguanil is a prodrug converted to cycloguanil, which inhibits dihydrofolate reductase in the parasite, blocking DNA synthesis. The combination synergistically kills blood-stage schizonts and inhibits liver-stage hypnozoites of P. falciparum.. ARAKODA is a Antimalarial that works by ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MALARONE PEDIATRIC and ARAKODA depend on the specific clinical indication. These are both Antimalarial agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MALARONE PEDIATRIC is: Adults: 250 mg atovaquone/100 mg proguanil orally once daily for 3 consecutive days for treatment; for prophylaxis, 250 mg/100 mg orally once daily starting 1-2 days before travel and continued for 7 days after leaving endemic area.. The standard adult dose of ARAKODA is: 400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MALARONE PEDIATRIC and ARAKODA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MALARONE PEDIATRIC is classified as Category C. MALARONE PEDIATRIC contains atovaquone and proguanil. Atovaquone is not teratogenic in animals, but proguanil is associated with increased risk of neural tube defects and other con. ARAKODA is classified as Category C. FDA Pregnancy Category C. First trimester: animal studies show fetal harm; human data insufficient. Second/third trimester: risk of fetal growth restriction; consider risk-benefit.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.